| Revenue growth | FY26 revenue ₹1,713cr, broadly flat to declining YoY. |
|---|---|
| Margins | Q4 EBITDA margin improved to 20.3%; FY26 at 12.9%. |
| Order book | Pharma order book remains intact despite shipment delays. |
| Demand visibility | Improving demand trends in API and CDMO segments for FY27. |
| Management confidence | Confident in recovery post-FDA resolution and inventory normalization. |
Growth
FY26 revenue ₹1,713cr; EBITDA ₹220cr (12.9% margin). Pharma revenue ₹1,021cr; Crop Protection ₹692cr.
Outlook
Targeting 5-6 DMF filings annually. HPAPI plant targeted for FY28. Guidance of ₹500cr Animal Health revenue.
Risks
US FDA warning letter at Bangalore; raw material price spikes in solvents; geopolitical volatility impacting supply.
Earnings Call filed with BSE, NSE: HIKAL. Summary written with AI assistance from the document.
Hikal Ltd: key numbers
- Share price
- ₹217.58
- Market cap
- ₹2,683 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -79.4×Sector 50.4×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 0.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Annual General Meeting
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal Production Started
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Earnings Call Transcript: Key Takeaways
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
- Call
- Guides 15% growth
Hikal Investor Presentation: Key Takeaways
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Q1 FY27 Results: Net Loss of ₹7.4 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹402.8 Cr (+5.9% YoY) and a net loss of ₹7.4 Cr for Q1 FY27.
- Key figure
- Net loss ₹7.4 Cr
Hikal Earnings Call: Key Takeaways
Hikal is navigating a difficult recovery phase, masked by a massive ₹47cr impairment and USFDA warning letter at Bangalore. While margins show sequential improvement, the core business remains stagnant and heavily reliant on regulatory resolution.